| Congenital agammaglobulinemia
Gammaplex vs Cutaquig
Side-by-side clinical, coverage, and cost comparison for congenital agammaglobulinemia.Deep comparison between: Gammaplex vs Cutaquig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCutaquig has a higher rate of injection site reactions vs Gammaplex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cutaquig but not Gammaplex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gammaplex
Cutaquig
At A Glance
IV infusion
Every 3-4 weeks
Immune globulin (IgG replacement)
SC injection
Weekly
Immune globulin (IGSC)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Primary immune deficiency disorder
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-800 mg/kg (3-8 mL/kg) IV every 3-4 weeks; initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.
Immune thrombocytopenic purpura 1 g/kg (10 mL/kg) IV on 2 consecutive days (total dose 2 g/kg); initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.
Primary immune deficiency disorder, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC dose based on pharmacokinetic and clinical response; for patients switching from IGIV, calculate initial weekly dose by dividing monthly IGIV dose by weeks between infusions and multiplying by adjustment factor of 1.30; for patients switching from IGSC, maintain same weekly dose; dosing interval from daily up to every other week.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Previous anaphylactic or severe systemic reaction to subcutaneous administration of human immune globulin or to any component of CUTAQUIG, including Polysorbate 80
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human globulin treatment
Adverse Reactions
Most common (>=5%) in PI Headache, migraine, pyrexia
Most common (>=5%) in ITP Headache, vomiting, pyrexia, nausea, arthralgia, dehydration
Serious Thrombotic events, hemolysis; in ITP subjects: headache, vomiting, dehydration
Postmarketing Tachycardia, thromboembolism, hypertension, flushing, nausea, chills, chest discomfort, pyrexia, back pain, polymyositis, headache, dyspnea, rash, urticaria
Most common (>=5%) Local infusion site reactions (redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, cough
Postmarketing Pancytopenia, leukopenia, hemolytic anemia, anaphylactic reaction, hypersensitivity reaction, angioneurotic edema, thromboembolism, Stevens-Johnson syndrome, aseptic meningitis, seizures, cardiac arrest, respiratory failure, pulmonary embolism, acute renal failure, dizziness, nausea, pruritus, fatigue
Pharmacology
Polyclonal human IgG that provides replacement therapy for primary humoral immunodeficiency via a broad spectrum of opsonic and neutralizing IgG antibodies against pathogens and their toxins through antigen binding and effector functions; the mechanism of action in both PI and ITP has not been fully elucidated.
Immune globulin replacement; CUTAQUIG supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, with IgG subclass distribution closely proportional to native human plasma, restoring abnormally low IgG levels to the normal range to help prevent infections in primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gammaplex
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Cutaquig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Gammaplex
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Cutaquig
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Gammaplex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Cutaquig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gammaplex.
$5/fillfill
Octapharma IgCares Co-Pay Assistance Program: CutaquigCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GammaplexView full Gammaplex profile
CutaquigView full Cutaquig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.